MedTrace Logo

Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission

NCT05596097 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-10-27

No results posted yet for this study

Summary

This trial is a single-center, single-arm, prospective clinical study to investigate the efficacy and safety of zanubrutinib maintenance therapy in patients with diffuse large B-cell lymphoma (DLBCL) in Initial remission. The patients were divided into two categories: 1) Zanubrutinib maintenance therapy was started after R-CHOP induction and consolidation therapy reached maximum efficacy; 2) Initiate zanubrutinib maintenance therapy after maximal response to induction and consolidation therapy with or without rituximab (R-chemo). Therefore, the data in this study will reflect the efficacy and safety of zanubrutinib in the maintenance treatment of DLBCL patients with initial remission, and will provide new insights into the clinical application of zanubrutinib.

Conditions

  • Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

DRUG

Zanubrutinib

Zanubrutinib, 180mg, bid, p.o., d1-28; Treatment cycles every 28 days

Sponsors & Collaborators

  • BeOne Medicines

    collaborator INDUSTRY

  • LanZhou University

    lead OTHER

Principal Investigators

  • Bei Liu, MD · The First Hospital of Lanzhou University,Lanzhou,Gansu,China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-30
Primary Completion
2024-10-20
Completion
2026-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05596097 on ClinicalTrials.gov